drugset / Trial / NCT00886821
A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics
RandomizedSingle-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type 2 diabetic patients.
Timeline
- Start
- 2008-10
- Primary completion
- 2011-06
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CVX-096 | Unknown | 0.1 mg | Subcutaneous |
| Subject | CVX-096 | Unknown | 36 mg | Subcutaneous |